The histone acetylranseferase hMOF acetylates Nrf2 and regulates anti‐drug responses in human non‐small cell lung cancer. (July 2014)
- Record Type:
- Journal Article
- Title:
- The histone acetylranseferase hMOF acetylates Nrf2 and regulates anti‐drug responses in human non‐small cell lung cancer. (July 2014)
- Main Title:
- The histone acetylranseferase hMOF acetylates Nrf2 and regulates anti‐drug responses in human non‐small cell lung cancer
- Authors:
- Chen, Zhiwei
Ye, Xiangyun
Tang, Naiwang
Shen, Shengping
Li, Ziming
Niu, Xiaomin
Lu, Shun
Xu, Ling - Abstract:
- <abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bph12661-sec-0001" sec-type="section"> <title>Background and Purpose</title> <p>The histone acetyltransferase MOF is a member of the MYST family. In mammals, MOF plays critical roles by acetylating histone H4 at K16 and non‐histone substrates such as p53. Here we have investigated the role of MOF in human lung cancer and possible new substrates of hMOF.</p> </sec> <sec id="bph12661-sec-0002" sec-type="section"> <title>Experimental Approach</title> <p>Samples of human non‐small cell lung cancer (NSCLC) were used to correlate MOF with clinicopathological parameters and NF–E2‐related factor 2 (Nrf2) downstream genes. 293T‐cells were used to study interactions between MOF and Nrf2, and acetylation of Nrf2 by MOF. Mouse embryonic fibroblast and A549 cells were utilized to assess involvement of MOF in antioxidative and anti‐drug responses. A549 cells were used to analysis the role of MOF in anti‐drug response <italic>in vitro</italic> and <italic>in vivo</italic>.</p> </sec> <sec id="bph12661-sec-0003" sec-type="section"> <title>Key Results</title> <p>hMOF was overexpressed in human NSCLC tissues and was associated with large tumour size, advanced disease stage and metastasis, and with poor prognosis. hMOF levels were positively correlated with Nrf2‐downstream genes. MOF/hMOF physically interacted with and acetylated Nrf2 at Lys<sup>588</sup>. MOF‐mediated acetylation increased nuclear<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bph12661-sec-0001" sec-type="section"> <title>Background and Purpose</title> <p>The histone acetyltransferase MOF is a member of the MYST family. In mammals, MOF plays critical roles by acetylating histone H4 at K16 and non‐histone substrates such as p53. Here we have investigated the role of MOF in human lung cancer and possible new substrates of hMOF.</p> </sec> <sec id="bph12661-sec-0002" sec-type="section"> <title>Experimental Approach</title> <p>Samples of human non‐small cell lung cancer (NSCLC) were used to correlate MOF with clinicopathological parameters and NF–E2‐related factor 2 (Nrf2) downstream genes. 293T‐cells were used to study interactions between MOF and Nrf2, and acetylation of Nrf2 by MOF. Mouse embryonic fibroblast and A549 cells were utilized to assess involvement of MOF in antioxidative and anti‐drug responses. A549 cells were used to analysis the role of MOF in anti‐drug response <italic>in vitro</italic> and <italic>in vivo</italic>.</p> </sec> <sec id="bph12661-sec-0003" sec-type="section"> <title>Key Results</title> <p>hMOF was overexpressed in human NSCLC tissues and was associated with large tumour size, advanced disease stage and metastasis, and with poor prognosis. hMOF levels were positively correlated with Nrf2‐downstream genes. MOF/hMOF physically interacted with and acetylated Nrf2 at Lys<sup>588</sup>. MOF‐mediated acetylation increased nuclear retention of Nrf2 and transcription of its downstream genes. Importantly, MOF/hMOF was essential for anti‐oxidative and anti‐drug responses <italic>in vitro</italic> and regulated tumour growth and drug resistance <italic>in vivo</italic> in an Nrf2‐dependent manner.</p> </sec> <sec id="bph12661-sec-0004" sec-type="section"> <title>Conclusion and Implications</title> <p>hMOF was overexpressed in human NSCLC and was a predictor of poor survival. hMOF‐mediated Nrf2 acetylation and nuclear retention are essential for anti‐oxidative and anti‐drug responses. hMOF may provide a therapeutic target for the treatment of NSCLC.</p> </sec> </abstract> … (more)
- Is Part Of:
- British journal of pharmacology. Volume 171:Number 13(2014:Jul.)
- Journal:
- British journal of pharmacology
- Issue:
- Volume 171:Number 13(2014:Jul.)
- Issue Display:
- Volume 171, Issue 13 (2014)
- Year:
- 2014
- Volume:
- 171
- Issue:
- 13
- Issue Sort Value:
- 2014-0171-0013-0000
- Page Start:
- 3196
- Page End:
- 3211
- Publication Date:
- 2014-07
- Subjects:
- Pharmacology -- Periodicals
Chemotherapy -- Periodicals
Drug Therapy -- Periodicals
Pharmacology -- Periodicals
615.1 - Journal URLs:
- http://bibpurl.oclc.org/web/21844 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1476-5381/issues ↗
http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=282&action=archive ↗
http://onlinelibrary.wiley.com/ ↗
http://www.nature.com/bjp/index.html ↗ - DOI:
- 10.1111/bph.12661 ↗
- Languages:
- English
- ISSNs:
- 0007-1188
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2314.700000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 3691.xml